Patients with heart failure require long-term medical treatment [1, 2]. Non-adherence to
medication is the main factor limiting treatment efficacy due to increased morbidity and …

According to the European Society of Cardiology guidelines dual antiplatelet therapy
(DAPT) for 12 months, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin …

The risk of ischemic events gradually decreases after acute coronary syndrome (ACS),
reaching a stable level after 1 month, while the risk of bleeding remains steady during the …

Introduction: Poor medication adherence is associated with unsatisfactory health outcomes,
elevated mortality, and high costs of medical care. This study aimed to assess the …

Previously the treatment with b-blockers, angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers and mineralocorticoid receptor antagonists, was shown to …

I read with great interest the letter to the editor entitled" Semaglutide as a chance for obesity
treatment" by Giordano U et al.[1]. Indeed, obesity is a major public health threat in many …

The 2021 Guidelines of European Society of Cardiology (ESC) for the diagnosis and
treatment of acute and chronic heart failure (HF) defined three major goals of treatment:(1) …

Abstract Treatment of patients with heart failure and reduced left ventricular ejection fraction
(HFrEF) aims to reduce mortality, prevent rehospitalizations due to heart failure (HF) …

Abstract Introduction: The 2021 European Society of Cardiology (ESC) guidelines on
cardiovascular disease prevention introduced significant changes compared to the previous …

Metabolic syndrome (MetS) is a cluster of modifiable cardiovascular risk factors including
obesity, hypertension, impaired glucose metabolism, and elevated non-high-density …